The percentages of IL-17A, IFN-γ, IL-4, and GM-CSF-producing cells in CD4+ T cells, and IL-17A and IFN-γ-producing cells in CD8+ T cells were not significantly different between MS patients in remission and HCs after Bonferroni–Dunn’s correction (Table 5). This evidence concerns the gene IFNG and myeloid sarcoma.